In patients with non-alcoholic fatty liver disease, liver stiffness directly correlates with the carotid plaque burden

نویسندگان

چکیده

Background and Aims : It is now well established that non-alcoholic fatty liver disease (NAFLD) associated with a significant increase in the risk of adverse cardiovascular events. NAFLD-specific scores, considering traditional nontraditional factors, are needed to improve patient care. Liver fibrosis may be an integrative indicator burden cardiometabolic factors. also represent subclinical atherosclerosis. The aim study was investigate relationships between stiffness carotid plaque patients NAFLD without atherosclerotic disease.Methods: A total 73 patients, 42 (57.5%) male 31 (42.5%) female, median age 48.5 (42.0-55.7) years, were included study. steatosis assessed non-invasively using ultrasound-based Hamaguchi score. investigated by transient elastography FibroScan®. All underwent duplex scan. Carotid area (cTPA) measured as burden.Conclusions: In middle-aged NAFLD, increased burden. disease. Methods: Conclusions:

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Serum leptin levels in psoriatic patients with non-alcoholic fatty liver disease

Background: The prevalence of non-alcoholic fatty liver disease is higher in patients with psoriasis than in the normal population. Serum leptin levels are higher in patients with psoriasis and in patients with non-alcoholic fatty liver. The purpose of this study was to determine the serum levels of leptin in psoriatic patients with and without non-alcoholic fatty liver.<span...

متن کامل

Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease

Increasing evidence suggests a role of intestinal dysbiosis in obesity and non-alcoholic fatty liver disease (NAFLD). But it remains unknown in nonobese NAFLD. This prospective, cross-sectional study sought to characterize differences in fecal microbiota between nonobese adult individuals with and without NAFLD and their potential association with metabolic markers of disease progression. A tot...

متن کامل

Prevalence of gallstone disease in the patients with non-alcoholic fatty liver disease (NAFLD) in Sanandaj: A case control study

Background and Aim: Nonalcoholic fatty liver disease (NAFLD) and gallstone disease (GD) are both highly prevalent in the general population and have many risk factors in common. The aim of this study was to evaluate the prevalence of GD in the patients with NAFLD. Materials and Methods: In this case-control study, our case group included 145 patients with NAFLD and control group consisted of 21...

متن کامل

Comparison of Diet Records between Patients with Non-alcoholic Fatty Liver Disease and Controls

Introduction: Non-alcoholic fatty liver disease (NAFLD) is considered to be a severe health threat across the world, the prevalence of which has significantly increased in recent years. Considering the role of diet in the pathogenesis of NAFLD, the present study aimed to evaluate and compare the dietary intakes of patients with NAFLD with healthy subjects. Methods:</str...

متن کامل

Comparing Effects of Medication Therapy and Exercise Training with Diet on Liver enzyme Levels and Liver Sonography in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

Background & Objectives: Non-alcoholic fatty liver disease, characterized by the deposition of fat in liver cells, can cause fibrosis, cirrhosis, and liver cell damage if not controlled. The aim of this study is to compare the effects of medication therapy and exercise training with diet on liver enzyme levels and liver sonography in patients with non-alcoholic fatty liver disease (NAFLD). Mate...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Atherosclerosis

سال: 2022

ISSN: ['0021-9150', '1879-1484']

DOI: https://doi.org/10.1016/j.atherosclerosis.2022.06.801